SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-18-054637
Filing Date
2018-08-31
Accepted
2018-08-31 08:21:32
Documents
67
Period of Report
2018-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q a18-18919_110q.htm 10-Q 1380769
2 EX-31.1 a18-18919_1ex31d1.htm EX-31.1 11347
3 EX-31.2 a18-18919_1ex31d2.htm EX-31.2 10851
4 EX-32.1 a18-18919_1ex32d1.htm EX-32.1 7189
5 EX-32.2 a18-18919_1ex32d2.htm EX-32.2 7181
  Complete submission text file 0001104659-18-054637.txt   6150553

Data Files

Seq Description Document Type Size
6 EX-101.INS ruby-20180630.xml EX-101.INS 1336162
7 EX-101.SCH ruby-20180630.xsd EX-101.SCH 47427
8 EX-101.CAL ruby-20180630_cal.xml EX-101.CAL 46722
9 EX-101.LAB ruby-20180630_lab.xml EX-101.LAB 442994
10 EX-101.PRE ruby-20180630_pre.xml EX-101.PRE 341238
11 EX-101.DEF ruby-20180630_def.xml EX-101.DEF 184200
Mailing Address 325 VASSAR STREET, SUITE 1A CAMBRIDGE MA 02139
Business Address 325 VASSAR STREET, SUITE 1A CAMBRIDGE MA 02139 617-679-9600
Rubius Therapeutics, Inc. (Filer) CIK: 0001709401 (see all company filings)

IRS No.: 042688109 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38586 | Film No.: 181048517
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences